Medtronic reports positive real-world study data for Endurant II stent

Medtronic has announced the findings of a long-term real-world study showing the benefits offered by its Endurant II abdominal aortic aneurysm stent graft system.

The five-year ENGAGE global registry evaluated more than 1,200 endovascular aortic repair patients, spanning 79 sites in 30 countries. It was initiated less than a year after the device's European approval, with clinical follow-up data spanning up to ten years.

Examining imaging follow-up data from approximately 500 patients, a 97.8 percent freedom rate from aneurysm-related mortality (ARM) was demonstrated, in addition to an 89.4 percent stable or decreased diameter aortic aneurysm sac rate at five years.

The data also demonstrated an 84.3 percent freedom from secondary endovascular procedures.

Study investigator Dr Philippe Cuypers, a vascular surgeon at Catharina Hospital in Eindhoven, said: "Out to five years, the ENGAGE data showed low ARM and secondary procedure rates. This further demonstrates both the benefit of the technique used with Endurant, as well as the durability of the graft itself."

The patient group involved in this study included those with challenging anatomies, who have historically been difficult to treat and are associated with limited eligibility for endovascular repair, as well as higher rates of secondary interventions.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.